Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York..
Read More
